

## **REMARKS**

### **The Present Invention**

The present invention is related to thiazolyl compounds useful as inhibitors of Tec family tyrosine kinases (especially inhibitors of Emt).

### **Amendments to the Claims**

Claim 16 has been cancelled. Claims 7, 9, 10, 12 and 13 have been amended to address a Restriction requirement. New claims 23-25 have been added. New claims 23-24 are directed at methods of using the compounds of the present invention in the treatment of a Tec family tyrosine kinase-associated disorder. These new claims find support in the specification as originally filed, for example, at page 1, lines 10-11, page 31, lines 8-15, and the original claims.

Accordingly, no new matter has been added by way of the new or amended claims.

Applicants note that new claims 23-25 are being added herein in view of the rejoinder procedures described in the *Official Gazette* notice dated March 26, 1996 (1184 O.G. 86). See MPEP §821.04.

### **The Pending Claims**

Claims 7-14, 17-19, and 23-25 are now pending in this application. Claims 7-14 relate to thiazolyl compounds useful as inhibitors of Tec family tyrosine kinases (especially inhibitors of Emt). Claims 17-19 relate to pharmaceutical compositions containing such compounds. New claims 23-25 relate to methods of using the thiazolyl compounds for the treatment of a Tec family tyrosine kinase-associated disorder.

### **The Office Action**

In the Office Action, claims 7-14 and 16-19 have been objected to as containing non-elected subject matter. The Office Action contends on page 7 that claims 7-14 and 16-19 involve more than one independent and distinct invention. However, the Examiner indicated they would be allowable if rewritten solely to the invention identified in the Office Action. Applicants respectfully submit that claims 7-14 and 16-19 do not involve more than one independent and distinct invention; rather, the claims are directed to different embodiments of a single invention. However, in order to

U.S.S.N: 10/027,982

Amendment and Response to Office Action dated May 16, 2003

expedite prosecution of the application, applicants have canceled claim 16 and amended claims 7, 9, 10, 12 and 13 as suggested by the Examiner to claim the invention identified in the Office Action.


Conclusion

In view of the amendments and remarks presented above, applicants respectfully submit that the pending claims are in condition for allowance. An early Office Action to that effect is, therefore, earnestly requested. If the Examiner does not agree that the application is now allowable, entry of the amendments is respectfully requested in order to place the claims in better form for consideration on appeal.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 and 1.17 that may be required in filing this paper to Deposit Account No. 19-3880.

If, in the opinion of the Examiner, a telephone conference with the undersigned would facilitate prosecution of this patent application, the Examiner's call would be welcomed.

Respectfully submitted,



Terence J. Bogie  
Attorney for Applicants  
Registration No. 44,544  
Telephone No. (609) 252-6385  
Facsimile No. (609) 252-4526

Date: August 7, 2003

**Please forward all future correspondence relating to this application to:**

Stephen B. Davis  
Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000